Jamie Layland
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jamie Layland has a total of 42 co-authors. Here are the top co-authors by number of shared publications:
Andrew MacIsaac
2 shared publicationsAndrew Wilson
2 shared publicationsChristine Jellis
2 shared publications- Jithendra Somaratne
Department of Cardiology, Auckland City Hospital, Auckland, New Zealand, adhb.govt.nz
2 shared publications Robert Whitbourn
2 shared publications- Alex McConnachie
Robertson Centre for Biostatistics, School of Health and Wellbeing, University of Glasgow, Glasgow, UK
1 shared publication
Latest Publications
- Open Access
- 22 June 2022
- Published by Springer Nature in Cardiology and Therapy
- Vol. 11 (3) , 319-335
High-Risk Coronary Plaque Features: A Narrative Review
Advances in coronary plaque imaging over the last few decades have led to an increased interest in the identification of novel high-risk plaque features that are associated with cardiovascular events. Existing practices focus on risk stratification and lipid monitoring for primary and secondary prevention of cardiac events, which is limited by a lack of assessment and treatment of vulnerable plaque. In this review, we summarize the multitude of studies that have identified plaque, haemodynamic and patient factors associated with risk of acute coronary syndrome. Future progress in multi-modal imaging strategies and in our understanding of high-risk plaque features could expand treatment options for coronary disease and improve patient outcomes.
- 22 June 2022
- Published by Springer Nature in Cardiology and Therapy
- Vol. 11 (3) , 319-335
Open AccessHigh-Risk Coronary Plaque Features: A Narrative Review
Advances in coronary plaque imaging over the last few decades have led to an increased interest in the identification of novel high-risk plaque features that are associated with cardiovascular events. Existing practices focus on risk stratification and lipid monitoring for primary and secondary prevention of cardiac events, which is limited by a lack of assessment and treatment of vulnerable plaque. In this review, we summarize the multitude of studies that have identified plaque, haemodynamic and patient factors associated with risk of acute coronary syndrome. Future progress in multi-modal imaging strategies and in our understanding of high-risk plaque features could expand treatment options for coronary disease and improve patient outcomes.
- Open Access
- 14 November 2015
- Published by Springer Nature in Cost Effectiveness and Resource Allocation
- Vol. 13 (1) , 1-9
Fractional flow reserve (FFR) versus angiography in guiding management to optimise outcomes in non-ST segment elevation myocardial infarction (FAMOUS-NSTEMI) developmental trial: cost-effectiveness using a mixed trial- and model-based methods
In the Fractional flow reserve (FFR) versus angiography in guiding management to optimise outcomes in non-ST elevation myocardial infarction (FAMOUS) clinical trial, FFR was shown to significantly reduce coronary revascularisation, compared to visual interpretation of standard coronary angiography without FFR. We estimated the cost-effectiveness from a UK National Health Service perspective, based on the results of FAMOUS. A mixed trial- and model-based approach using decision and statistical modelling was used. Within-trial (1-year) costs and QALYs were assembled at the individual level and then modelled on subsequent management strategy [coronary artery bypass graft (CABG), percutaneous coronary intervention (PCI) or medical therapy (MT)] and major adverse coronary events (death, MI, stroke and revascularisation). One-year resource uses included: material, hospitalisation, medical, health professional service use and events. Utilities were derived from individual EQ5D responses. Unit costs were derived from the literature. Outcomes were extended to a lifetime on the basis of MACE during the 1st year. Costs and QALYs were modelled using generalized linear models whilst MACE was modelled using logistic regression. The analysis adopted a payer perspective. Costs and outcomes were discounted at 3.5 %. Costs were related to the subsequent management strategy and MACE whilst QALYs were not. FFR led to a modest cost increase, albeit an imprecise increase, over both the trial [£112 (−£129 to £357)] and lifetime horizons [£133 (−£199 to £499)]. FFR led to a small, albeit imprecise, increase in QALYs over both the trial [0.02 (−0.03 to 0.06)] and lifetime horizons [0.03 (−0.21 to 0.28)]. The mean ICER was £7516/QALY and £4290/QALY over the trial and lifetime horizons, respectively. Decision remained high; FFR had 64 and 59 % probability of cost-effectiveness over trial and lifetime horizons, respectively. FFR was cost-effective at the mean, albeit with considerable decision uncertainty. Uncertainty can be reduced with more information on long-term health events.
- 14 November 2015
- Published by Springer Nature in Cost Effectiveness and Resource Allocation
- Vol. 13 (1) , 1-9
Open AccessFractional flow reserve (FFR) versus angiography in guiding management to optimise outcomes in non-ST segment elevation myocardial infarction (FAMOUS-NSTEMI) developmental trial: cost-effectiveness using a mixed trial- and model-based methods
In the Fractional flow reserve (FFR) versus angiography in guiding management to optimise outcomes in non-ST elevation myocardial infarction (FAMOUS) clinical trial, FFR was shown to significantly reduce coronary revascularisation, compared to visual interpretation of standard coronary angiography without FFR. We estimated the cost-effectiveness from a UK National Health Service perspective, based on the results of FAMOUS. A mixed trial- and model-based approach using decision and statistical modelling was used. Within-trial (1-year) costs and QALYs were assembled at the individual level and then modelled on subsequent management strategy [coronary artery bypass graft (CABG), percutaneous coronary intervention (PCI) or medical therapy (MT)] and major adverse coronary events (death, MI, stroke and revascularisation). One-year resource uses included: material, hospitalisation, medical, health professional service use and events. Utilities were derived from individual EQ5D responses. Unit costs were derived from the literature. Outcomes were extended to a lifetime on the basis of MACE during the 1st year. Costs and QALYs were modelled using generalized linear models whilst MACE was modelled using logistic regression. The analysis adopted a payer perspective. Costs and outcomes were discounted at 3.5 %. Costs were related to the subsequent management strategy and MACE whilst QALYs were not. FFR led to a modest cost increase, albeit an imprecise increase, over both the trial [£112 (−£129 to £357)] and lifetime horizons [£133 (−£199 to £499)]. FFR led to a small, albeit imprecise, increase in QALYs over both the trial [0.02 (−0.03 to 0.06)] and lifetime horizons [0.03 (−0.21 to 0.28)]. The mean ICER was £7516/QALY and £4290/QALY over the trial and lifetime horizons, respectively. Decision remained high; FFR had 64 and 59 % probability of cost-effectiveness over trial and lifetime horizons, respectively. FFR was cost-effective at the mean, albeit with considerable decision uncertainty. Uncertainty can be reduced with more information on long-term health events.
- 1 October 2013
- Published by Elsevier in International Journal of Cardiology
- Vol. 169 (2) , 121-125
The resting status of the coronary microcirculation is a predictor of microcirculatory function following elective PCI for stable angina
- 1 October 2013
- Published by Elsevier in International Journal of Cardiology
- Vol. 169 (2) , 121-125
The resting status of the coronary microcirculation is a predictor of microcirculatory function following elective PCI for stable angina
- 1 August 2013
- Published by Elsevier in International Journal of Cardiology
- Vol. 167 (3) , 951-953
Impact of right atrial pressure on decision-making using fractional flow reserve (FFR) in elective percutaneous intervention
- 1 August 2013
- Published by Elsevier in International Journal of Cardiology
- Vol. 167 (3) , 951-953
Impact of right atrial pressure on decision-making using fractional flow reserve (FFR) in elective percutaneous intervention
- 1 September 2012
- Vol. 24 (9) , E205-6
Novel method of rescuing kinked guide catheter from axillary artery in transradial coronary intervention: the balloon retrieval technique.
This case illustrates a novel and innovative method of retrieving a kinked guiding catheter in transradial intervention without the need for vascular snare.
- 1 September 2012
- Vol. 24 (9) , E205-6
Novel method of rescuing kinked guide catheter from axillary artery in transradial coronary intervention: the balloon retrieval technique.
This case illustrates a novel and innovative method of retrieving a kinked guiding catheter in transradial intervention without the need for vascular snare.
- 1 January 2012
- Published by Elsevier in Cardiovascular Revascularization Medicine
- Vol. 13 (1) , 66-68
Takotsubo cardiomyopathy: reversible elevation in microcirculatory resistance
- 1 January 2012
- Published by Elsevier in Cardiovascular Revascularization Medicine
- Vol. 13 (1) , 66-68
Takotsubo cardiomyopathy: reversible elevation in microcirculatory resistance
- 3 May 2010
- Published by Wiley in Medical Journal of Australia
- Vol. 192 (9) , 520-525
Percutaneous management of aortic stenosis in high‐risk patients
As the population ages, the prevalence of aortic stenosis is increasing. There is an unmet clinical need for the treatment of aortic stenosis in high‐risk patients, who are often older, frail and ha...
- 3 May 2010
- Published by Wiley in Medical Journal of Australia
- Vol. 192 (9) , 520-525
Percutaneous management of aortic stenosis in high‐risk patients
As the population ages, the prevalence of aortic stenosis is increasing. There is an unmet clinical need for the treatment of aortic stenosis in high‐risk patients, who are often older, frail and ha...
- 1 January 2009
- Published by Elsevier in Cardiovascular Revascularization Medicine
- Vol. 10 (1) , 55-57
Extremely late drug-eluting stent thrombosis: 2037 days after deployment
- 1 January 2009
- Published by Elsevier in Cardiovascular Revascularization Medicine
- Vol. 10 (1) , 55-57
Extremely late drug-eluting stent thrombosis: 2037 days after deployment
- 31 December 2008
- Published by Elsevier in Heart, Lung and Circulation
- Vol. 17, S146
Early Effects of Bosentan on Pulmonary Arterial Hypertension in a Real World Setting
- 31 December 2008
- Published by Elsevier in Heart, Lung and Circulation
- Vol. 17, S146
Early Effects of Bosentan on Pulmonary Arterial Hypertension in a Real World Setting